Post-transplant Autologous Cytokine-induced Killer (CIK) Cells for Treatment of High Risk Hematologic Malignancies
Status:
Completed
Trial end date:
2011-03-01
Target enrollment:
Participant gender:
Summary
The purpose of the study is to conduct a phase I study of adoptive immunotherapy with
autologous, ex-vivo expanded cytokine-induced killer (CIK) cells to reduce the relapse rate
in autologous stem cell transplant patients with high-risk hematologic malignancies.